A busy second day of the JP Morgan conference saw Thermo Fisher's Marc Casper discuss the firm's R&D focus and Exact Sciences' Kevin Conroy discuss plans for Cologuard sales growth.
The company said it completed approximately 292,000 Cologuard tests during the fourth quarter.
Test volume for the firm's Cologuard colorectal cancer screening test rose 49 percent year over year during the quarter.
Biomatrica's sample collection tubes ensure quality preservation of circulating tumor DNA and cells, promoting high-quality liquid biopsy results, Exact said.
Pfizer will join Exact's sales reps to increase adoption of the colorectal cancer test; Wall Street reacted by sending Exact's shares up sharply.
The company said volumes for its Cologuard colon cancer screening test rose 59 percent to 215,000 during the quarter.
The company said it plans to use the net proceeds for general corporate purposes, including for working capital and possible acquisitions.
The American Cancer Society today lowered the recommended age for screening patients at average risk for the disease to 45 from 50 years old.
Positive first quarter earnings reports lifted many stocks of life science tools firms even as the broader biotechnology market suffered.
Chinese state news agency Xinhua reports that a preliminary investigation has found He Jiankui performed his gene-editing work illegally.
John Mendelsohn, a former president of the University of Texas MD Anderson Cancer Center, has died, the New York Times reports.
Identical twins receive different estimates of ancestry from the same direct-to-consumer genetic testing firms, CBC reports.
In PNAS this week: chromosomal features of maize, adaptations in the vinous-throated parrotbill, and more.